Treatments
For patients in the US suffering from opioid use disorder (OUD) and adjacent diseases or conditions, Orexo provides innovative treatment solutions. The daily work is supported by a fully-fledged team including medical affairs, market access and a sales force covering the states in the US with the highest prevalence of OUD. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners.
Treatment portfolio
|
Product |
Indication |
Technology |
Partner |
Phases |
Approved and/or launched |
|||||||
|
Explorative |
Preclinical |
Clinical development |
Registration |
US |
EU |
RoW |
||||||
|
OUD |
Sublingual platform |
 |
||||||||||
|
Breakthrough cancer pain |
Sublingual platform |
 |
||||||||||
|
Insomnia |
Sublingual platform |
 |
||||||||||
|
DMHP1 |
OUD/Alcohol misuse/Depression |
Broca platform |
 |
|||||||||
2 questions to Robert DeLuca, President of Orexo US Inc.
What are your priorities for 2024 and coming year 2025?
For 2024 my focus as the year winds down is to deliver on the revenue targets. For Zubsolv, we will continue to ensure healthcare providers continue to have the opportunity and information necessary to make the decision to prescribing Zubsolv for their patients. Additionally, we are preparing the organization and the marketplace for the launch of OX124.
What would you like to achieve in a 5 year horizon?
Our priorities have been and will continue to focus on patient needs and bringing unique solutions to assist in their path to recovery.
For example, I am excited about the opportunity to bring OX124 to the opioid overdose rescue market because the patient need in the US is so significant. Launching OX124, along with Zubsolv revenues, provides us the opportunity for revenue growth and market expansion that could outperform prior years internal revenue targets. Continuing to deliver solid pharma profits and cash flow enables us to prepare for new launches and the R&D team to continue to develop new medicines.
>90%
of revenues in 2023 related to SDG 3.5*
*Target 3.5, Prevent and treat substance abuse
Orexo's Zubsolv has the potential to help
6.1* million
people in the US towards an OUD free life
*Number of people suffering from opioid dependence in the US in 2023
1Digital Mental Health Programs
